Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice
Abstract Multiple sclerosis (MS) is the most common causes of non-traumatic disability in young adults worldwide. MS pathophysiologies include the formation of inflammatory lesions, axonal damage and demyelination, and blood brain barrier (BBB) disruption. Coagulation proteins, including factor (F)XII, can serve as important mediators of the adaptive immune response during neuroinflammation. Indeed, plasma FXII levels are increased during relapse in relapsing-remitting MS patients, and previous studies showed that reducing FXII levels was protective in a murine model of MS, experimental autoimmune encephalomyelitis (EAE). Our objective was to determine if pharmacological targeting of FXI, a major substrate of activated FXII (FXIIa), improves neurological function and attenuates CNS damage in the setting of EAE. EAE was induced in male mice using murine myelin oligodendrocyte glycoprotein peptides combined with heat-inactivated Mycobacterium tuberculosis and pertussis toxin. Upon onset of symptoms, mice were treated every other day intravenously with anti-FXI antibody, 14E11, or saline. Disease scores were recorded daily until euthanasia for ex vivo analyses of inflammation. Compared to the vehicle control, 14E11 treatment reduced the clinical severity of EAE and total mononuclear cells, including $ CD11b^{+} $$ CD45^{high} $ macrophage/microglia and $ CD4^{+} $ T cell numbers in brain. Following pharmacological targeting of FXI, BBB disruption was reduced, as measured by decreased axonal damage and fibrin(ogen) accumulation in the spinal cord. These data demonstrate that pharmacological inhibition of FXI reduces disease severity, immune cell migration, axonal damage, and BBB disruption in mice with EAE. Thus, therapeutic agents targeting FXI and FXII may provide a useful approach for treating autoimmune and neurologic disorders..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Metabolic brain disease - 38(2023), 7 vom: 21. Juni, Seite 2383-2391 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kohs, Tia C. L. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11011-023-01251-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2145570462 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2145570462 | ||
| 003 | DE-627 | ||
| 005 | 20240118105433.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11011-023-01251-1 |2 doi | |
| 035 | |a (DE-627)OLC2145570462 | ||
| 035 | |a (DE-He213)s11011-023-01251-1-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00$jMedizin: Allgemeines |2 bkl | ||
| 100 | 1 | |a Kohs, Tia C. L. |e verfasserin |0 (orcid)0000-0002-7900-0016 |4 aut | |
| 245 | 1 | 0 | |a Pharmacological targeting of coagulation factor XI attenuates experimental autoimmune encephalomyelitis in mice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract Multiple sclerosis (MS) is the most common causes of non-traumatic disability in young adults worldwide. MS pathophysiologies include the formation of inflammatory lesions, axonal damage and demyelination, and blood brain barrier (BBB) disruption. Coagulation proteins, including factor (F)XII, can serve as important mediators of the adaptive immune response during neuroinflammation. Indeed, plasma FXII levels are increased during relapse in relapsing-remitting MS patients, and previous studies showed that reducing FXII levels was protective in a murine model of MS, experimental autoimmune encephalomyelitis (EAE). Our objective was to determine if pharmacological targeting of FXI, a major substrate of activated FXII (FXIIa), improves neurological function and attenuates CNS damage in the setting of EAE. EAE was induced in male mice using murine myelin oligodendrocyte glycoprotein peptides combined with heat-inactivated Mycobacterium tuberculosis and pertussis toxin. Upon onset of symptoms, mice were treated every other day intravenously with anti-FXI antibody, 14E11, or saline. Disease scores were recorded daily until euthanasia for ex vivo analyses of inflammation. Compared to the vehicle control, 14E11 treatment reduced the clinical severity of EAE and total mononuclear cells, including $ CD11b^{+} $$ CD45^{high} $ macrophage/microglia and $ CD4^{+} $ T cell numbers in brain. Following pharmacological targeting of FXI, BBB disruption was reduced, as measured by decreased axonal damage and fibrin(ogen) accumulation in the spinal cord. These data demonstrate that pharmacological inhibition of FXI reduces disease severity, immune cell migration, axonal damage, and BBB disruption in mice with EAE. Thus, therapeutic agents targeting FXI and FXII may provide a useful approach for treating autoimmune and neurologic disorders. | ||
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a EAE | |
| 650 | 4 | |a Thrombin | |
| 650 | 4 | |a Factor XI | |
| 700 | 1 | |a Fallon, Meghan E. |0 (orcid)0000-0002-5868-7576 |4 aut | |
| 700 | 1 | |a Oseas, Ethan C. |0 (orcid)0000-0002-6712-7028 |4 aut | |
| 700 | 1 | |a Healy, Laura D. |0 (orcid)0000-0002-3162-7100 |4 aut | |
| 700 | 1 | |a Tucker, Erik I. |0 (orcid)0000-0003-0532-113X |4 aut | |
| 700 | 1 | |a Gailani, David |0 (orcid)0000-0001-8142-8014 |4 aut | |
| 700 | 1 | |a McCarty, Owen J. T. |0 (orcid)0000-0001-9481-0124 |4 aut | |
| 700 | 1 | |a Vandenbark, Arthur A. |0 (orcid)0000-0002-1207-6817 |4 aut | |
| 700 | 1 | |a Offner, Halina |0 (orcid)0000-0001-6472-6079 |4 aut | |
| 700 | 1 | |a Verbout, Norah G. |0 (orcid)0000-0002-8170-9331 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Metabolic brain disease |d Springer US, 1986 |g 38(2023), 7 vom: 21. Juni, Seite 2383-2391 |w (DE-627)168086751 |w (DE-600)632824-6 |w (DE-576)518182371 |x 0885-7490 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2023 |g number:7 |g day:21 |g month:06 |g pages:2383-2391 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11011-023-01251-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 936 | b | k | |a 44.00$jMedizin: Allgemeines |q VZ |0 106409646 |0 (DE-625)106409646 |
| 951 | |a AR | ||
| 952 | |d 38 |j 2023 |e 7 |b 21 |c 06 |h 2383-2391 | ||